Physician profile
Edwin Tan
NPI 1629074240
$5,992.07
in general payments reported to CMS, 2019-2025
36 companies · $1,814 in 2025
The $1,814 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,027 · 2020: $602 · 2021: $157 · 2022: $123 · 2023: $614 · 2024: $1,655 · 2025: $1,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,082.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,054.50 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $874.84 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Pfizer INC. | $851.73 | 2019-2025 | |
| Novo Nordisk INC | $504.98 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $428.15 | 2021-2025 | Vraylar, Viberzi, Linzess |
| Boehringer Ingelheim Pharmaceuticals, INC. | $366.72 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $244.43 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $180.71 | 2020 | |
| Merck Sharp & Dohme LLC | $177.85 | 2019-2025 | Gardasil 9, Vaxelis, Rotateq |
| Lilly USA, LLC | $174.95 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $146.63 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Teva Pharmaceuticals USA, INC. | $129.01 | 2023-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $114.47 | 2020-2025 | Trintellix |
| Astellas Pharma US INC | $88.19 | 2023-2025 | Veozah |
| Dexcom, INC. | $80.38 | 2023-2025 | Dexcom G6 Transmitter |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Tan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.